BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17920164)

  • 1. Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.
    Benoit AC; Huang Y; Maneewatchararangsri S; Tapchaisri P; Anderson R
    Vaccine; 2007 Nov; 25(45):7754-62. PubMed ID: 17920164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
    Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
    Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection.
    Kong X; Hellermann GR; Patton G; Kumar M; Behera A; Randall TS; Zhang J; Lockey RF; Mohapatra SS
    Virol J; 2005 Feb; 2():3. PubMed ID: 15701174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.
    Jafri HS; Chavez-Bueno S; Mejias A; Gomez AM; Rios AM; Nassi SS; Yusuf M; Kapur P; Hardy RD; Hatfield J; Rogers BB; Krisher K; Ramilo O
    J Infect Dis; 2004 May; 189(10):1856-65. PubMed ID: 15122522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
    van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
    J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).
    Benoit A; Huang Y; Proctor J; Rowden G; Anderson R
    Clin Exp Immunol; 2006 Jul; 145(1):147-54. PubMed ID: 16792685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
    Peebles RS; Sheller JR; Collins RD; Jarzecka K; Mitchell DB; Graham BS
    J Infect Dis; 2000 Sep; 182(3):671-7. PubMed ID: 10950758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
    Moore ML; Peebles RS
    Pharmacol Ther; 2006 Nov; 112(2):405-24. PubMed ID: 16820210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of respiratory syncytial virus on the activity of matrix metalloproteinase in mice.
    Li W; Shen HH
    Chin Med J (Engl); 2007 Jan; 120(1):5-11. PubMed ID: 17254480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
    Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M
    Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus infection in a murine model of cystic fibrosis.
    Colasurdo GN; Fullmer JJ; Elidemir O; Atkins C; Khan AM; Stark JM
    J Med Virol; 2006 May; 78(5):651-8. PubMed ID: 16555274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
    Ikemura T; Schwarze J; Makela M; Kanehiro A; Joetham A; Ohmori K; Gelfand EW
    J Pharmacol Exp Ther; 2000 Aug; 294(2):701-6. PubMed ID: 10900250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.